Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPH - Cytoclonal Pharmaceutics -- Ignore unavailable to you. Want to Upgrade?

To: Axxel who wrote (213)	6/30/1998 10:07:00 PM
From: SPEEDRACER	Respond to of 428

I've traded cyph and the warrants for some time now. I sold out a few months ago at 11. Today I couldn't help myself and bought 6k under 7. I really think this is a gimmee at these prices!!!!!! SPEEDY========================

To: Axxel who wrote (213)	6/30/1998 11:07:00 PM
From: Doug Coughlan	Read Replies (2) \| Respond to of 428

Bloomberg News stated that CYPH was rated a "strong buy" in new coverage by analyst Josh Moses at Janssen Meyers with a 6 month price target of $15. I'll take a strong buy recommendation from any legitimate firm, but it would be nicer if it came from a more disinterested firm. I mean picture poor Josh trying to explain to his bosses Janssen and Meyers that he has initiated coverage of a company in which they control forty plus percent of the outstanding shares with a neutral or god forbid a sell recommendation! So while I'm sure we all appreciate the recommendation, it does not come without some bias.